Cardiogenic shock after 5-fluorouracil administration: a case report and literature review

Eur Heart J Case Rep. 2023 Dec 13;7(12):ytad596. doi: 10.1093/ehjcr/ytad596. eCollection 2023 Dec.

Abstract

Background: Cardiogenic shock is a rare adverse event of 5-fluorouracil (5-FU) administration. Because of its rare entity, little is known about epidemiologic and clinical features of 5-FU-induced cardiogenic shock, and recommendations about specific treatment are missing.

Case summary: We present a case of cardiogenic shock and ventricular arrhythmia due to 5-FU-induced toxic cardiomyopathy treated with vasopressor and inotropic drugs in combination with intra-aortic balloon pump. Because of persistent haemodynamic instability, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and Impella were implanted as a bridge to recovery. Systolic function recovered completely and the patient was weaned successfully.

Discussion: This case demonstrates toxic cardiomyopathy as a rare and potentially lethal cardiac adverse event of 5-FU administration. This case emphasizes the importance of mechanical support as bridging therapy to recovery of cardiac function.

Keywords: 5-Fluorouracil; Cardiogenic shock; Cardiotoxicity; Case report; VA-ECMO.

Publication types

  • Case Reports